{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T22:57:50Z","timestamp":1776293870869,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:00:00Z","timestamp":1590278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:00:00Z","timestamp":1590278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Grant from MEXT, Japan","award":["18H02928"],"award-info":[{"award-number":["18H02928"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18059412"],"award-info":[{"award-number":["18059412"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18bm0304004h0006"],"award-info":[{"award-number":["18bm0304004h0006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18bm0104001h0006"],"award-info":[{"award-number":["18bm0104001h0006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18bm0804006h0002"],"award-info":[{"award-number":["18bm0804006h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal-dominant disease characterized by heterotopic ossification (HO) in soft tissues and caused by a mutation of the <jats:italic>ACVR1A\/ALK2<\/jats:italic> gene. Activin-A is a key molecule for initiating the process of HO via the activation of mTOR, while rapamycin, an mTOR inhibitor, effectively inhibits the Activin-A-induced HO. However, few reports have verified the effect of rapamycin on FOP in clinical perspectives.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We investigated the effect of rapamycin for different clinical situations by using mice conditionally expressing human mutant ACVR1A\/ALK2 gene. We also compared the effect of rapamycin between early and episode-initiated treatments for each situation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Continuous, episode-independent administration of rapamycin reduced the incidence and severity of HO in the natural course of FOP mice. Pinch-injury induced HO not only at the injured sites, but also in the contralateral limbs and provoked a prolonged production of Activin-A in inflammatory cells. Although both early and injury-initiated treatment of rapamycin suppressed HO in the injured sites, the former was more effective at preventing HO in the contralateral limbs. Rapamycin was also effective at reducing the volume of recurrent HO after the surgical resection of injury-induced HO, for which the early treatment was more effective.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our study suggested that prophylactic treatment will be a choice of method for the clinical application of rapamycin for FOP.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-01406-8","type":"journal-article","created":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T11:02:52Z","timestamp":1590318172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prophylactic treatment of rapamycin ameliorates naturally developing and episode -induced heterotopic ossification in mice expressing human mutant ACVR1"],"prefix":"10.1186","volume":"15","author":[{"given":"Hirotsugu","family":"Maekawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanae","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Yoshitomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0184-9685","authenticated-orcid":false,"given":"Junya","family":"Toguchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,24]]},"reference":[{"issue":"Suppl 2","key":"1406_CR1","first-page":"437","volume":"10","author":"RJ Pignolo","year":"2013","unstructured":"Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013;10(Suppl 2):437\u201348.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"1","key":"1406_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13023-017-0674-5","volume":"12","author":"G Baujat","year":"2017","unstructured":"Baujat G, Choquet R, Bou\u00e9e S, Jeanbat V, Courouve L, Ruel A, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12(1):123.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"1406_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrrheum.2010.122","volume":"6","author":"EM Shore","year":"2010","unstructured":"Shore EM, Kaplan FS. Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol. 2010;6(9):518\u201327.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1406_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1242\/dmm.010280","volume":"5","author":"FS Kaplan","year":"2012","unstructured":"Kaplan FS, Chakkalakal SA, Shore EM. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis Model Mech. 2012;5(6):756\u201362.","journal-title":"Dis Model Mech"},{"key":"1406_CR5","first-page":"1","volume":"4","author":"The International Clinical Consortium on FOP","year":"2011","unstructured":"The International Clinical Consortium on FOP. The medical Management of Fibrodysplasia Ossificans Progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP. 2011;4:1\u2013100.","journal-title":"Clin Proc Intl Clin Consort FOP"},{"issue":"5","key":"1406_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525\u20137.","journal-title":"Nat Genet"},{"issue":"3","key":"1406_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/humu.20868","volume":"30","author":"FS Kaplan","year":"2009","unstructured":"Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30(3):379\u201390.","journal-title":"Hum Mutat"},{"issue":"1","key":"1406_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1750-1172-8-190","volume":"8","author":"Y Matsumoto","year":"2013","unstructured":"Matsumoto Y, Hayashi Y, Schlieve CR, Ikeya M, Kim H, Nguyen TD, et al. Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J Rare Dis. 2013;8(1):190.","journal-title":"Orphanet J Rare Dis."},{"issue":"6","key":"1406_CR9","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/stem.1981","volume":"33","author":"Y Matsumoto","year":"2015","unstructured":"Matsumoto Y, Ikeya M, Hino K, Horigome K, Fukuta M, Watanabe M, et al. New protocol to optimize iPS cells for genome analysis of Fibrodysplasia Ossificans Progressiva. Stem Cells. 2015;33(6):1730\u201342.","journal-title":"Stem Cells"},{"issue":"50","key":"1406_CR10","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1073\/pnas.1510540112","volume":"112","author":"K Hino","year":"2015","unstructured":"Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M, et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci U S A. 2015;112(50):15438\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"303","key":"1406_CR11","doi-asserted-by":"publisher","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","volume":"7","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell SJ, Idone V, Wolken DM, Huang L, Kim HJ, Wang L, et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015;7(303):303ra137.","journal-title":"Sci Transl Med"},{"issue":"Pt 17","key":"1406_CR12","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1242\/jcs.094789","volume":"125","author":"M Antsiferova","year":"2012","unstructured":"Antsiferova M, Werner S. The bright and the dark sides of activin in wound healing and cancer. J Cell Sci. 2012;125(Pt 17):3929\u201337.","journal-title":"J Cell Sci"},{"issue":"2","key":"1406_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/jbmr.3304","volume":"33","author":"MR Convente","year":"2018","unstructured":"Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, et al. Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr1(R206H) mouse model of Fibrodysplasia Ossificans Progressiva. J Bone Miner Res. 2018;33(2):269\u201382.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1406_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41467-018-02872-2","volume":"9","author":"JB Lees-Shepard","year":"2018","unstructured":"Lees-Shepard JB, Yamamoto M, Biswas AA, Stoessel SJ, Nicholas SE, Cogswell CA, et al. Activin-dependent signaling in fibro\/adipogenic progenitors causes fibrodysplasia ossificans progressiva. Nat Commun. 2018;9(1):471.","journal-title":"Nat Commun"},{"issue":"12","key":"1406_CR15","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/nm.1888","volume":"14","author":"PB Yu","year":"2008","unstructured":"Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008;14(12):1363\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"1406_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nchembio.2007.54","volume":"4","author":"PB Yu","year":"2008","unstructured":"Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008;4(1):33\u201341.","journal-title":"Nat Chem Biol"},{"key":"1406_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.bone.2017.09.004","volume":"109","author":"E Williams","year":"2018","unstructured":"Williams E, Bullock AN. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone. 2018;109:251\u20138.","journal-title":"Bone."},{"issue":"4","key":"1406_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nm.2334","volume":"17","author":"K Shimono","year":"2011","unstructured":"Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med. 2011;17(4):454\u201360.","journal-title":"Nat Med"},{"issue":"9","key":"1406_CR19","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jbmr.2820","volume":"31","author":"SA Chakkalakal","year":"2016","unstructured":"Chakkalakal SA, Uchibe K, Convente MR, Zhang D, Economides AN, Kaplan FS, et al. Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) mutation. J Bone Miner Res. 2016;31(9):1666\u201375.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1406_CR20","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI93521","volume":"127","author":"K Hino","year":"2017","unstructured":"Hino K, Horigome K, Nishio M, Komura S, Nagata S, Zhao C, et al. Activin-a enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. J Clin Invest. 2017;127(9):3339\u201352.","journal-title":"J Clin Invest"},{"issue":"5","key":"1406_CR21","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.stemcr.2018.10.007","volume":"11","author":"K Hino","year":"2018","unstructured":"Hino K, Zhao C, Horigome K, Nishio M, Okanishi Y, Nagata S, et al. An mTOR signaling modulator suppressed heterotopic ossification of Fibrodysplasia Ossificans Progressiva. Stem Cell Rep. 2018;11(5):1106\u201319.","journal-title":"Stem Cell Rep"},{"issue":"3","key":"1406_CR22","doi-asserted-by":"publisher","first-page":"E338","DOI":"10.1073\/pnas.1515397113","volume":"113","author":"S Agarwal","year":"2016","unstructured":"Agarwal S, Loder S, Brownley C, Cholok D, Mangiavini L, Li J, et al. Inhibition of Hif1\u03b1 prevents both trauma-induced and genetic heterotopic ossification. Proc Natl Acad Sci U S A. 2016;113(3):E338\u201347.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"1406_CR23","doi-asserted-by":"publisher","first-page":"e89805","DOI":"10.1172\/jci.insight.89805","volume":"1","author":"S Agarwal","year":"2016","unstructured":"Agarwal S, Cholok D, Loder S, Li J, Breuler C, Chung MT, et al. mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration. JCI Insight. 2016;1(20):e89805.","journal-title":"JCI Insight"},{"key":"1406_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00003086-199801000-00005","volume":"346","author":"FH Gannon","year":"1998","unstructured":"Gannon FH, Valentine BA, Shore EM, Zasloff MA, Kaplan FS. Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1998;346:19\u201325.","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"1406_CR25","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1542\/peds.2005-0469","volume":"116","author":"JA Kitterman","year":"2005","unstructured":"Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics. 2005;116(5):e654\u201361.","journal-title":"Pediatrics."},{"issue":"5940","key":"1406_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1126\/science.1175202","volume":"325","author":"FK Swirski","year":"2009","unstructured":"Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325(5940):612\u20136.","journal-title":"Science."},{"issue":"6","key":"1406_CR27","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00467-011-1811-3","volume":"26","author":"D Gonz\u00e1lez","year":"2011","unstructured":"Gonz\u00e1lez D, Garc\u00eda CD, Az\u00f3car M, Waller S, Alonso A, Ariceta G, et al. Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol. 2011;26(6):961\u20136.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"1406_CR28","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00467-013-2505-9","volume":"29","author":"L Pape","year":"2014","unstructured":"Pape L, Ahlenstiel T. mTOR inhibitors in pediatric kidney transplantation. Pediatr Nephrol. 2014;29(7):1119\u201329.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"1406_CR29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00467-007-0456-8","volume":"22","author":"O Alvarez-Garcia","year":"2007","unstructured":"Alvarez-Garcia O, Carbajo-Perez E, Garcia E, Gil H, Molinos I, Rodriguez J, et al. Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol. 2007;22(7):954\u201361.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"1406_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ki.2010.173","volume":"78","author":"O Alvarez-Garc\u0131a","year":"2010","unstructured":"Alvarez-Garc\u0131a O, Garc\u0131a-Lopez E, Loredo V, Gil-Pena H, Rodr\u0131guez-Suarez J, Ordonez FA, et al. Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate. Kidney Int. 2010;78(6):561\u20138.","journal-title":"Kidney Int"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01406-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01406-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01406-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T23:22:52Z","timestamp":1621812172000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01406-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1406"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01406-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,24]]},"assertion":[{"value":"15 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No human materials were used in this study, and all animal experiments were approved by the institutional animal committee of Kyoto University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}